

DIN EN ISO 14155:2026-08 (E)

Clinical investigation of medical devices for human subjects - Good clinical practice (ISO 14155:2026)

Contents	Page
Foreword	vi
Introduction	viii
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 Summary of good clinical practice principles	9
5 Ethical considerations	10
5.1 General.....	10
5.2 Improper influence or inducement.....	10
5.3 Compensation and additional health care	10
5.4 Registration in publicly accessible database	11
5.5 Responsibilities.....	11
5.6 Communication with the ethics committee	11
5.6.1 General	11
5.6.2 Initial EC submission	11
5.6.3 Information to be obtained from the EC	12
5.6.4 Continuing communication with the EC.....	12
5.6.5 Continuing information to be obtained from the EC.....	12
5.7 Vulnerable populations.....	12
5.8 Informed consent.....	13
5.8.1 General	13
5.8.2 Process of obtaining informed consent	13
5.8.3 Special circumstances for informed consent.....	14
5.8.4 Information to be provided to the subject	15
5.8.5 Informed consent signature.....	16
5.8.6 New information.....	17
6 Clinical investigation planning	17
6.1 General.....	17
6.2 Risk management.....	17
6.2.1 General.....	17
6.2.2 Risks related to the use of the investigational device and their disclosure.....	18
6.2.3 Risks related to clinical procedures required by the CIP outside routine clinical practice	18
6.2.4 Risks related to the clinical investigation process	19
6.3 Justification for the design of the clinical investigation.....	19
6.4 Clinical investigation plan.....	19
6.5 Investigator's brochure.....	20
6.6 Case report forms	20
6.7 Monitoring plan	20
6.8 Investigation site selection.....	21
6.9 Agreement(s).....	22
6.10 Labelling.....	22
6.11 Data monitoring committee	22
6.12 Clinical events committee	22
7 Clinical investigation conduct	23
7.1 General.....	23
7.2 Investigation site initiation.....	23
7.3 Investigation site monitoring.....	23

7.4	Adverse events and device deficiencies	23
7.4.1	Signals requiring immediate action	23
7.4.2	Adverse events	23
7.4.3	Device deficiencies	24
7.4.4	Risk assessment process for potentially unacceptable risks related to the use of the investigational device	24
7.4.5	Management of risks related to clinical procedures required by the CIP outside routine clinical practice	25
7.5	Clinical investigation documents and documentation	25
7.5.1	Amendments	25
7.5.2	Subject identification log	25
7.5.3	Source documents	26
7.6	Additional members of the investigation site team	26
7.7	Subject privacy and confidentiality of data	26
7.8	Document and data control	26
7.8.1	Traceability of documents and data	26
7.8.2	Recording of data	26
7.8.3	Electronic clinical data systems	27
7.9	Investigational device accountability	28
7.10	Accounting for subjects	28
7.11	Auditing	28
8	Suspension, termination and close-out of the clinical investigation	29
8.1	Completion of the clinical investigation	29
8.2	Suspension or premature termination of the clinical investigation	29
8.2.1	General	29
8.2.2	Procedure for suspension	29
8.2.3	Procedure for premature termination	30
8.2.4	Procedure for resuming the clinical investigation after suspension	30
8.3	Routine close-out	31
8.4	Clinical investigation report	31
8.5	Risk assessment and conclusions	32
8.6	Document retention	32
9	Responsibilities of the sponsor	32
9.1	Clinical quality management	32
9.2	Clinical investigation planning and conduct	33
9.2.1	Selection and training of clinical personnel	33
9.2.2	Preparation of documents and materials	34
9.2.3	Conduct of clinical investigation	34
9.2.4	Monitoring	35
9.2.5	Safety evaluation and reporting	37
9.2.6	Clinical investigation close-out	38
9.3	Outsourcing of duties and functions	38
9.4	Communication with regulatory authorities	39
10	Responsibilities of the principal investigator	39
10.1	General	39
10.2	Qualification of the principal investigator	39
10.3	Qualification of investigation site	39
10.4	Communication with the EC	40
10.5	Informed consent process	40
10.6	Compliance with the CIP	40
10.7	Medical care of subjects	41
10.8	Safety reporting	42
	Annex A (normative) Clinical investigation plan	43
	Annex B (normative) Investigator's brochure	51

Annex C (informative) Case report forms	54
Annex D (normative) Clinical investigation report.....	56
Annex E (informative) Essential clinical investigation documents	61
Annex F (informative) Adverse event categorization.....	67
Annex G (informative) EC responsibilities.....	69
Annex H (informative) Application of ISO 14971 during clinical investigations.....	73
Annex I (informative) Clinical development stages.....	74
Annex J (informative) Clinical investigation audits.....	79
Annex K (informative) Clinical investigation design considerations.....	82
Bibliography.....	84